Fig. 2

Identification of clinical variables informative for response to CMA administration. a Distribution of ADAS-Cog scores over visits for patients with ALT level ≤ 16 IU/l (upper panel) and ALT > 16 IU/l (lower panel) at visit 1. b Between-visit changes of ADAS-Cog score in AD patients stratified by other various clinical variables. Only those clinical variable groupings resulted in a more significant change of ADAS-Cog in the CMA group compared to the placebo group is shown (P < 0.05). The colour scale indicates log2 fold change of ADAS-Cog score between visits. Statistical significance between visits was determined by a paired t-test across individuals who attended both visits. Asterisks indicate a statistical significance of P < 0.05